基本信息
浏览量:49
职业迁徙
个人简介
I am a Professor of Mental Health at Griffith University and a registered pharmacist in Australia and New Zealand. I have worked as a health practitioner, educator, and researcher in mental health and pharmacy practice for over 25 years and am nationally and internationally recognised for my expertise in mental health and its impact on physical wellbeing, person-centred care, and pharmacy practice. My leadership bridges clinical practice, public health, and social sciences; my clinical foundation gives me workforce credibility and a unique appreciation of interdisciplinary issues. My research focuses on community engagement, quality improvement, professional practice, workforce development, and capacity building. These themes connect with the common goal of improving representation, rights, and outcomes for consumers and carers, and health professionals.
I provide health promotion and education for health practitioners, students, and community groups to improve their understanding of mental illness, associated stigma and the physical health comorbidities and life expectancy concerns. This work has been recognised with appointment as Ambassador, Equally Well (2021). In 2021 I was also elected Council Member for the College of Mental Health Pharmacy UK, responsible for the Education portfolio (International). I have also been awarded a Distinguished Investigator Award from the Health Services Research Association of Australia and New Zealand.
I was awarded my PhD late in my professional career (in 2009) whilst working full-time and followed a non-traditional career path, establishing a highly successful research centre in a public health service in New Zealand that I directed for over 10 years. The centre was primarily self-funding from the award of competitive and consultancy research grants of over $2.5 million NZD. Since moving to Australia in December 2010 my international profile and reputation have contributed to ongoing success in securing highly competitive national research funding totalling more than $20 million in the last five years.
I am CI on a $591K MRFF grant (MOVEMENT: 2022-2026) for guideline development integrating evidence-based exercise therapy within mental health teams and increasing workforce capability and capacity, with cost-effective approaches. I am also CI on a $2.5M MRFF grant (ACTMed: 2021-2025) which will refocus medication safety as a proactive, team-based process through enhanced collaboration between consumers, pharmacists and GPs using innovative IT solutions and a real-time dashboard. I am leading the co-design of the national roadmap for the ALIVE National Centre for Mental Health Research Translation, a $10M NHMRC Special Initiative in Mental Health (2021-2025). I am CI on a $1.07m NHMRC Partnership Project (2020-2024) to test the feasibility of accurately diagnosing FASD in remote Aboriginal primary healthcare settings. This work will upskill primary care practitioners to ensure that First Nations children living in rural/remote regions have equitable access to early diagnosis and management for FASD. I have led 5 large multi-state projects funded by the Australian Government Department of Health; most recently; one involving community pharmacists working with consumers with severe mental illness to improve physical health and medication problems (PharMIbridge RCT: 2020-2022); and a $3.4 million grant (IMeRSe: 2017-2020) to test the feasibility of a culturally responsive medication review service, delivered by pharmacists, integrated with Aboriginal health services in rural, remote and urban settings. This facilitated improved health and wellbeing for Indigenous people within a holistic framework.
My innovative research has made significant impacts in clinical and community practice; contributing new knowledge to improving mental health and professional pharmacy service provision and policy, person-centered care, and consequently consumer/carer outcomes. A particular strength is my inclusion of industry and community in the co-design of research and education programs; exemplified by three successful grants from the Queensland Mental Health Commission who identify consumer and community involvement as an eligibility criterion. I was also central to the establishment of the Lived Experience Network (as part of the Centre for Mental Health), to support engagement and involvement of consumers and communities in mental health research undertaken at Griffith University.
Examples of my research impact and translation into policy and practice include:
- working with international colleagues to develop a consensus statement [https://doi.org/10.1503%2Fjpn.200061] on the use of clozapine during the COVID-19 pandemic which was implemented by the New Zealand Ministry of Health [https://www.medsafe.govt.nz/safety/Alerts/ClozapineDatasheetUpdates.asp#Clozapine].
- exploring the psychotropic medication burden from adult cohorts discharged from a Queensland mental health unit. In acknowledgment of the role and contribution of mental health pharmacists in improving the quality use of medications in mental health settings, in 2019, the FTE resourcing of mental health pharmacists in this service setting was increased from 3.0 to 4.5 – the first real increase in more than 15 years.
- leading a research program that explored the use of the national Return of Unwanted Medicines (RUM) scheme through auditing RUM bins from all Australian states/territories; and a general population survey of public awareness and attitudes towards storage and disposal of unwanted medicines including interviews with high-medication user respondents. This research informed the development of a national public awareness campaign about the safe disposal of unwanted medicines via the national RUM program available in every local pharmacy in Australia (Return of Expired and Unwanted Medicine | Home [returnmed.com.au]). In the 6-months following the campaign launch there was a 10% increase in unwanted medicines returned via the program.
I provide health promotion and education for health practitioners, students, and community groups to improve their understanding of mental illness, associated stigma and the physical health comorbidities and life expectancy concerns. This work has been recognised with appointment as Ambassador, Equally Well (2021). In 2021 I was also elected Council Member for the College of Mental Health Pharmacy UK, responsible for the Education portfolio (International). I have also been awarded a Distinguished Investigator Award from the Health Services Research Association of Australia and New Zealand.
I was awarded my PhD late in my professional career (in 2009) whilst working full-time and followed a non-traditional career path, establishing a highly successful research centre in a public health service in New Zealand that I directed for over 10 years. The centre was primarily self-funding from the award of competitive and consultancy research grants of over $2.5 million NZD. Since moving to Australia in December 2010 my international profile and reputation have contributed to ongoing success in securing highly competitive national research funding totalling more than $20 million in the last five years.
I am CI on a $591K MRFF grant (MOVEMENT: 2022-2026) for guideline development integrating evidence-based exercise therapy within mental health teams and increasing workforce capability and capacity, with cost-effective approaches. I am also CI on a $2.5M MRFF grant (ACTMed: 2021-2025) which will refocus medication safety as a proactive, team-based process through enhanced collaboration between consumers, pharmacists and GPs using innovative IT solutions and a real-time dashboard. I am leading the co-design of the national roadmap for the ALIVE National Centre for Mental Health Research Translation, a $10M NHMRC Special Initiative in Mental Health (2021-2025). I am CI on a $1.07m NHMRC Partnership Project (2020-2024) to test the feasibility of accurately diagnosing FASD in remote Aboriginal primary healthcare settings. This work will upskill primary care practitioners to ensure that First Nations children living in rural/remote regions have equitable access to early diagnosis and management for FASD. I have led 5 large multi-state projects funded by the Australian Government Department of Health; most recently; one involving community pharmacists working with consumers with severe mental illness to improve physical health and medication problems (PharMIbridge RCT: 2020-2022); and a $3.4 million grant (IMeRSe: 2017-2020) to test the feasibility of a culturally responsive medication review service, delivered by pharmacists, integrated with Aboriginal health services in rural, remote and urban settings. This facilitated improved health and wellbeing for Indigenous people within a holistic framework.
My innovative research has made significant impacts in clinical and community practice; contributing new knowledge to improving mental health and professional pharmacy service provision and policy, person-centered care, and consequently consumer/carer outcomes. A particular strength is my inclusion of industry and community in the co-design of research and education programs; exemplified by three successful grants from the Queensland Mental Health Commission who identify consumer and community involvement as an eligibility criterion. I was also central to the establishment of the Lived Experience Network (as part of the Centre for Mental Health), to support engagement and involvement of consumers and communities in mental health research undertaken at Griffith University.
Examples of my research impact and translation into policy and practice include:
- working with international colleagues to develop a consensus statement [https://doi.org/10.1503%2Fjpn.200061] on the use of clozapine during the COVID-19 pandemic which was implemented by the New Zealand Ministry of Health [https://www.medsafe.govt.nz/safety/Alerts/ClozapineDatasheetUpdates.asp#Clozapine].
- exploring the psychotropic medication burden from adult cohorts discharged from a Queensland mental health unit. In acknowledgment of the role and contribution of mental health pharmacists in improving the quality use of medications in mental health settings, in 2019, the FTE resourcing of mental health pharmacists in this service setting was increased from 3.0 to 4.5 – the first real increase in more than 15 years.
- leading a research program that explored the use of the national Return of Unwanted Medicines (RUM) scheme through auditing RUM bins from all Australian states/territories; and a general population survey of public awareness and attitudes towards storage and disposal of unwanted medicines including interviews with high-medication user respondents. This research informed the development of a national public awareness campaign about the safe disposal of unwanted medicines via the national RUM program available in every local pharmacy in Australia (Return of Expired and Unwanted Medicine | Home [returnmed.com.au]). In the 6-months following the campaign launch there was a 10% increase in unwanted medicines returned via the program.
研究兴趣
论文共 236 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Victoria J Palmer,Amanda J Wheeler, Dana Jazayeri,Amelia Gulliver,Kelsey Hegarty, Joshua Moorhouse, Phillip Orcher,Michelle Banfield, ALIVE National Centre for Mental Health Research Translation Investigator Group
Journal of mental health (Abingdon, England)pp.1-17, (2024)
Ricki Ng,Sarira El-Den,Jack C. Collins,Victoria Stewart,Sara S. McMillan,Jie Hu,Amanda J. Wheeler, Claire L. O'Reilly
Research in Social and Administrative Pharmacy (2024)
Ricki Ng,Sarira El-Den,Jack C. Collins,Sara S. McMillan,Jie Hu,Amanda J. Wheeler, Claire L. O’Reilly
International Journal of Clinical Pharmacypp.1-10, (2024)
Research in Social and Administrative Pharmacyno. 7 (2023): 15-E1087
引用2浏览0引用
2
0
Research in Social and Administrative Pharmacyno. 7 (2023): 10-E1082
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn